Effect of 24-week treatment with telmisartan on myocardial structure and function: Relationship to insertion/deletion polymorphism of the angiotensin-converting enzyme gene

Journal of International Medical Research

Volumn 33, Issue SUPPL. 1, 2005, Pages

  Conrady, A O ^a   Kiselev, I O ^a   Usachev, N I ^a   Krutikov, A N ^a   Yakovleva, O I ^a   Polunicheva, E V ^a   Ovchinnikova, O A ^a   Panov, A V ^a  

^a PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

ACE gene; Angiotensin II receptor blocker; Arterial hypertension; Genetics; Insertion deletion polymorphism; Left ventricular hypertrophy; Telmisartan

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; TELMISARTAN;

ADULT; ARTICLE; BLOOD FLOW; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLE; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFECT; ECHOCARDIOGRAPHY; ENZYME POLYMORPHISM; ESSENTIAL HYPERTENSION; FEMALE; GENE DELETION; GENE INSERTION; GENOTYPE; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART MUSCLE; HUMAN; M MODE ECHOCARDIOGRAPHY; MALE; OPEN STUDY;

EID: 25844483960     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/14732300050330s105     Document Type: Article

References (37)

1. Hollenberg NK, Sever PS: The past, present and future of hypertension management: a potential role for AT(1)-receptor antagonists. J Renin Angiotensin Aldosterone Syst 2000; 1: 5-10.
2. Smith DHG, Matzek KM, Kempthorne-Rawson J: Dose response and safety of telmisartan in patients with mild to moderate hypertension. J Clin Pharmacol 2000; 40: 1380-1390.
3. Burnier M, Maillard M: The comparative pharmacology of angiotensin II receptor antagonists. Blood Press 2001; 10 (Suppl 1): 6-11.
4. Rodby RA, Rohde RD, Clarke WR, Hunsicker LG, Anzalone DA, Atkins RC, et al: The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics. Nephrol Dial Transplant 2000; 15: 487-497.
5. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
6. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
7. Viberti G, Wheeldon NM: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672-678.
8. Barnett AH: Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study. Acta Diabetol 2005; 42 (Suppl 1): S42-S49.
9. McInnes GT: Clinical potential: angiotensin converting enzyme inhibitor or angiotensin II antagonist? J Hypertens 2001; 19 (Suppl 1): S61-S67.
10. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
11. Thurmann PA, Kenedi P, Schmidt A, Harder S, Rietbrock N: Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98: 2037-2042.
12. Devereux RB, Okin PM, Roman MJ: Left ventricular hypertrophy as a surrogate endpoint in hypertension. Clin Exp Hypertens 1999; 21: 583-593.
13. Baudin B: New aspects on angiotensin-converting enzyme: from gene to disease. Clin Chem Lab Med 2002; 40: 256-265.
14. Sasaki M, Oki T, Iuchi A, Tabuta T, Yamada H, Manabe K, et al: Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies. J Hypertens 1996; 14: 1403-1408.
15. Kohno M, Yokokuwa K, Minami M, Kano H, Yasunari K, Hanehira T, et al: Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors. Am J Med 1999; 106: 544-549.
16. Devereux RB, Reicheck N: Echocardiographic determination of left ventricular mass in man. Circulation 1977; 55: 613-618.
17. Levy D, Savage DD, Garrison RJ, Anderson KM, Kannel WB, Castelli WP: Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol 1987; 59: 956-960.
18. Agabiti-Rosei E, Muiesan ML: Hypertensive left ventricular hypertrophy: pathophysiological and clinical issues. Blood Press 2001; 10: 288-298.
19. Schmieder RE, Messerli FH: Hypertension and the heart. J Hum Hypertens 2000; 14: 597-604.
20. Fleischmann EH, Schmieder RE: Are all antihypertensive drug classes equal in reducing left ventricular hypertrophy? Curr Cardiol Rep 2002; 4: 474-478.
21. Cuspidi C, Muiesan ML, Valagussa L, Salvetti M, Di Biagio C, Agabiti-Rosei E, et al: Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002; 20: 2293-2300.
22. Bohm M, Lippoldt A, Wienen W, Ganten D, Bader M: Reduction of cardiac hypertrophy in TGR(mREN2)27 by angiotensin II receptor blockade. Mol Cell Biochem 1996; 163/164: 217-221.
23. Wagner J, Drab M, Bohlender J, Amann K, Wienen W, Ganten D: Effects of AT1 receptor blockade on blood pressure and the renin - angiotensin system in spontaneously hypertensive rats of the stroke prone strain. Clin Exp Hypertens 1998; 20: 205-221.
24. Amende I, Chu V, Morgan JP, Hampton TG: Angiotensin II AT1 receptor blockade attenuates isoproterenol-induced cardiac hypertrophy in mice. Eur Heart J 2000; 21 (Abstract Suppl): 401.
25. Wienen W, Richard S, Champeroux P, Audeval-Gerard C: Comparative antihypertensive and renoprotective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic rats. J Renin Angiotensin Aldosterone Syst 2001; 2: 31-36.
26. Petrovic J, Popovic Z, Petrovic D, Djuric D: Telmisartan - influence on endothelial dysfunction in hypertensive patients. J Renin Angiotensin Aldosterone Syst 2000; 1: 74.
27. Galzerano D, Tammaro P, Cerciello A, Breglio R, Mallardo M, Lama D, et al: Freehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre study. J Hum Hypertens 2004; 18: 53-59.
28. Ivanova OV, Fomicheva OA, Sergakova LM, Chernova NA, Rogoza AN, Karpov YA: Angiotensin II receptor blocker telmisartan: effect on blood pressure profile and left ventricular hypertrophy in patients with arterial hypertension. J Int Med Res 2005; 33 (Suppl 1): 21A-29A.
29. Mattioli AV, Zennaro M, Bonatti S, Bonetti L, Mattioli G: Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan. Int J Cardiol 2004; 97: 383-388.
30. Martina B, Dieterle T, Sigle J-P, Surber C, Battegay E: Effects of telmisartan and losartan on left ventricular mass in mild-to-moderate hypertension. Cardiology 2003; 99: 169-170.
31. Mallion JM, Siche JP, Lacourciere Y, the Telmisartan Blood Pressure Monitoring Group: ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999; 13: 657-664.
32. Littlejohn TW, Mroczek W, Marbury T, VanderMaelen CP, Dubiel RF: A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. Can J Cardiol 2000; 16: 1123-1132.
33. White WB, Lacourciere Y, Davidai G: Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens 2004; 17: 347-353.
34. Panov AV, Conrady AO, Usatchev NI, Kruticov AN, Polunicheva EV: Long-term telmisartan treatment and cardiac structure in patients with essential hypertension. J Renin Angiotensin Aldosterone Syst 2001; 2: 75.
35. Petrovic J, Petrovic D, Vukovic N, Zivanovic B, Dregicevic J, Vasiljevic Z, et al: Ventricular and vascular remodelling - effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients. J Int Med Res 2005; 33 (Suppl 1): 39A-49A.
36. Staessen JA, Ginocchio G, Wang JG, Saavedra AP, Soubrier F, Vlietinck R, et al: Genetic variability in the renin - angiotensin system: prevalence of alleles and genotypes. J Cardiovasc Risk 1997; 4: 401-422.
37. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-1346.